SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: billkirn who wrote (502)3/19/1997 6:46:00 AM
From: Pete Holm   of 6136
 
Interesting question, billkirn. The FDA hates combination drugs. The process is difficult and the combination must prove synergy. On the other hand, this combination is as close to what the FDA wants as you can get. To the second part of your question, I don't know if there are any plans from a combo pill.

As to the combination therapy studies, I only know a few facts. It was a four-year clinical trial. The first few patients will be on therapy for 4 years next month. Obviously, these patients have done well and this part is well known. The next part of the study is a bit more difficult. They plan to take patients who have undetectable levels of the virus and remove all therapies. This is called a "Challange". They should know within a few months if the virus re-emerges or if the patients are cured of AIDS.

One problem they are having is that none of the patients in the trial wants to stop therapy. Why should they risk it?

No one really feels that any patient will be found "Cured", but rather AIDS will be just another chronic problem like arthritis. A relatively normal life as long as they remain on the therapy.

By the way, Viracept is being studied with all the other PIs. It is just that the best results are being seen with the AGPH/ROHHY combination.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News